TACE联合微波消融及仑伐替尼治疗中晚期肝癌的效果观察  

Effect Observation of TACE Combined with Microwave Ablation and Lenvatinib in the Treatment of Middle and Advanced Liver Cancer

作　　者：何均[1] 解长佶[1] 周新文[1] HE Jun;XIE Changji;ZHOU Xinwen(Jiangxi Cancer Hospital,Nanchang 330029,China;不详)

机构地区：[1]江西省肿瘤医院,江西南昌330029

出　　处：《中国医学创新》2023年第31期24-27,共4页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(202130738)。

摘　　要：目的:观察肝动脉化疗栓塞(TACE)联合微波消融及仑伐替尼治疗中晚期肝癌的效果。方法:选取江西省肿瘤医院2020年5月—2021年5月收治的80例中晚期肝癌患者,依随机数字表法分为对照组、试验组,每组40例。对照组接受TACE联合微波消融治疗,试验组接受TACE联合微波消融及仑伐替尼治疗;对比两组临床疗效、肿瘤标志物[癌胚抗原(CEA)、甲胎蛋白(AFP)]水平、肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)]及12个月生存率。结果:治疗结束6个月时,试验组客观缓解率、疾病控制率均较对照组高,差异均有统计学意义(P<0.05);试验组治疗1个月CEA、AFP、ALT、AST水平均较对照组低,差异均有统计学意义(P<0.05);试验组12个月生存率较对照组高,差异均有统计学意义(P<0.05)。结论:中晚期肝癌患者采用TACE联合微波消融及仑伐替尼治疗效果较好,可降低肿瘤标志物水平,提高肝功能,改善预后。Objective:To observe the efficacy of transcatheter arterial chemoembolization(TACE)combined with microwave ablation and Lenvatinib in the treatment of middle and advanced liver cancer.Method:A total of 80 patients with middle and advanced liver cancer admitted to Jiangxi Cancer Hospital from May 2020 to May 2021 were selected and divided into the control group and the experimental group according to random number table method,with 40 cases in each group.The control group received TACE combined with microwave ablation,and the experimental group received TACE combined with microwave ablation and Lenvatinib.Clinical efficacy,tumor marker[carcinoembryonic antigen(CEA),alpha-fetoprotein(AFP)]levels,liver function indexes[alanine transaminase(ALT),aspartate transaminase(AST)]and 12-month survival rate were compared between the two groups.Result:At 6 months after the end of treatment,the objective remission rate and disease control rate of the experimental group were higher than those of the control group,the differences were statistically significant(P<0.05).The levels of CEA,AFP,ALT and AST in the experimental group were lower than those in the control group after 1 month of treatment,the differences were statistically significant(P<0.05).The 12-month survival rate of the experimental group was higher than that of control group,the difference was statistically significant(P<0.05).Conclusion:TACE combined with microwave ablation and Lenvatinib can reduce the level of tumor markers,improve liver function and improve prognosis in patients with middle and advanced liver cancer.

关 键 词：中晚期肝癌 肝动脉化疗栓塞 微波消融 仑伐替尼 肿瘤标志物 生存期 

分 类 号：R735.7[医药卫生—肿瘤]